Camlin Fine Sciences narrows standalone loss to ₹3,296.62 lakh
The company reported a consolidated net profit of ₹2,762.72 lakh, driven by gains from the liquidation of CPS Europe.
— 3 earlier stories on Camlin Fine Sciences Ltd. →What's new
- Standalone net loss narrowed from ₹7,631.05 lakh in the prior year.
- Standalone revenue fell to ₹83,791.82 lakh from ₹88,649.13 lakh.
- The board appointed a new CFO and re-designated the existing finance chief.
Why this matters
The consolidated profit is a result of one-time liquidation gains rather than core operational growth. The revenue decline shows the company is still working through persistent sales pressure.
What we're watching
- Whether the new finance leadership addresses the revenue contraction.
- Core margin performance excluding the impact of discontinued operations.
- Future updates on the company's operational restructuring.
The full read
Camlin Fine Sciences reported a standalone net loss of ₹3,296.62 lakh for FY2025-26, an improvement over the ₹7,631.05 lakh loss recorded in the prior year. Revenue continued to slide, dropping to ₹83,791.82 lakh from ₹88,649.13 lakh. The company posted a consolidated net profit of ₹2,762.72 lakh, a figure influenced by a one-time gain from the liquidation of CPS Europe. The board also initiated a management restructuring, appointing a new CFO and re-designating the existing finance head. These results are routine and contain no surprises. The core challenge remains the persistent decline in revenue, which the new finance team will need to address as the company works through its operational hurdles.
Questions answered
- What drove the consolidated net profit?
- The profit of ₹2,762.72 lakh was driven by gains from the liquidation of CPS Europe, a discontinued operation.
- How did standalone performance change year-over-year?
- Standalone net loss narrowed to ₹3,296.62 lakh from ₹7,631.05 lakh in the previous year, while revenue fell to ₹83,791.82 lakh from ₹88,649.13 lakh.
- What management changes were announced?
- The board appointed a new CFO and re-designated the current CFO, marking a shift in the finance leadership structure.
- Are these results a surprise to the market?
- No. The filing is a routine financial disclosure that aligns with market expectations.
Story so far
All notes on CAMLINFINE →- 26 May 2026 · 4:43 PM IST Camlin Fine Sciences narrows standalone loss to ₹3,296.62 lakh
- 1d ago Camlin Fine Sciences blames logistics and phenol costs for sales hit
- 4d ago Camlin Fine Sciences cuts vanillin price guidance as costs surge
- 4d ago Camlin Fine Sciences narrows standalone loss as consolidation gains hit